Durable glycaemic control is critical to morbidity and mortality risk reduction in the long-term management of patients withtype2diabetes.Oralmetforminisoftenusedasfirst-line treatment [1], but loss of glucose-lowering efficacy over time is common [2], and stepwise therapy intensification with a sulphonylurea (SU) and/or insulin add-on therapy may be required to restore glycaemic control [3]; however, loss of SU glucose-lowering efficacy can occur after only 1year [2]. In addition, SU and insulin therapies are frequently associated withweightgainandanincreasedincidenceofhypoglycaemia [1]. Poor treatment tolerability may result in poor patient adherencetotreatmentandfurtherdeteriorationofglycaemic control[4,5].